11:30 AM ET
Earnings Call
▶ Call
Ocugen Earnings Call: Key Takeaways
Ocugen is transitioning to a late-stage clinical company with three Phase 3 programs, targeting BLA filings by 2028 and leveraging international licensing for non-dilutive capital.
- Call
- Nov 4, 2026, 8:30 AM ET